

Biomimetic Synthesis of Indole Alkaloids: Dihydromancunine


By RICHARD T. BROWN,* C. LYN CHAPPLE, and ANTONIOS A. CHARALAMBIDES

(Department of Chemistry, The University, Manchester M13 9PL)

Summary Dihydromancunine (**2a**), a model for a proposed biosynthetic intermediate, has been synthesised from vincoside and converted into *Corynanthé* indole alkaloids in a biomimetic sequence; hirsutine (**6b**) and dihydrocorynantheine (**6c**) have also been synthesised.

In a recent communication¹ we suggested that a pentacyclic amino-acetal (**2c**) would be a plausible biosynthetic intermediate on the route from vincoside to *Corynanthé* indole alkaloids. Evidence supporting this suggestion has now been provided by the synthesis of a dihydro-derivative (**2a**) of the hypothetical intermediate, mancunine, and more

importantly, its subsequent ready conversion into a standard *Corynanthé* structure. Condensation of dihydrosecologanin with *N*^b-benzyltryptamine afforded *N*^b-benzyl-18,19-dihydrovincoside (**1a**) $[\alpha]_D^{25} -108^\circ$ (MeOH), further characterised as the crystalline tetra-acetate, m.p. 203—205°, $[\alpha]_D^{25} -97^\circ$ (CHCl₃), and identified by correlation with the known vincoside lactam.² Removal of the sugar with β -glucosidase yielded a mixture of two readily interconvertible aglycones (**1b**) and (**1c**) which on hydrogenolysis with Pd-C in methanolic acetic acid gave 20 α -dihydromancunine (**2a**), m.p. 174—176°, $[\alpha]_D^{25} +266^\circ$ (CHCl₃), together with a trace of 3 β -dihydrovallesiachotamine (**7**).



The structure of dihydromancunine was elucidated by i.r., u.v., c.d., ^1H and ^{13}C n.m.r., and mass spectra, and finally established by the chemical correlation with corynantheidine (6a) below.

In agreement with an amino-acetal function the u.v. spectrum of (2a) did not show an immediate shift on addition of alkali, but an ionised β -hydroxyacrylate chromophore slowly developed over a period of hours. This indicated that gradual ring-opening to the enamine (4a) was occurring, which eventually resulted in conversion into the vallesiacotamine derivative (7). Accordingly prolonged treatment of (2a) with NaBH_4 in MeOH intercepted the intermediate (3) and afforded a compound with the *Corynanthe* structure (5b), $[\alpha]_D^{25} +15^\circ$ (MeOH). Subsequent epimerisation of 3-H by treatment with $\text{Pb}(\text{OAc})_4$ followed by NaBH_4 yielded dihydroisocorynantheine (5a), identical with that obtained from corynantheidine (6a) by acid-catalysed cleavage of the enol ether and borohydride reduction. In addition to establishing the structure this sequence showed that 20-H had been inverted from β to α in the conversion of (1a). Reduction of dihydromancunine (2a) in CH_3OD incorporated only one deuterium (at C-16) into the product, proving that no epimerisation occurred at this stage and dihydromancunine was already 20 α .

The configuration of the aglycones (1) at C-20 was almost certainly β , since methylation of both with diazomethane gave the same enol ether, which on catalytic hydrogenation afforded only hirsutine (6b), m.p. 105–107°, $[\alpha]_D^{25} +66^\circ$ (CHCl_3).^{1,3,4} Final proof of the C-20 stereochemistry was obtained by 3-H epimerisation of hirsutine as above to dihydrocorynantheine (6c), m.p. 109–111°, $[\alpha]_D^{25} +23.5^\circ$ (MeOH)⁴ and comparison of both with authentic samples.

Hence the inversion at C-20 is probably occurring when N-4 cyclises to C-21. The initially formed 20 β -dihydromancunine (2b) has an axial ethyl group which can, however, be changed to a more stable equatorial orientation by epimerisation *via* the enamine (4a) to the 20 α -isomer (2a). *In vivo* mancunine would presumably undergo an analogous opening of the ether bridge to give a 3 β -dehydrogeissoschizine (4b), which could then be transformed into the different *Corynanthe* alkaloids by various combinations of reduction, methylation, cyclisation, and 3-H epimerisation.

We thank Drs. J. D. Phillipson and R. Goutarel for generous gifts of alkaloids and the S.R.C. for a post-doctoral fellowship (A.A.C.).

(Received, 24th June 1974; Com. 739.)

¹ R. T. Brown and C. L. Chapple, *J.C.S. Chem. Comm.*, 1973, 886.

² W. P. Blackstock, R. T. Brown, and G. K. Lee, *Chem. Comm.*, 1971, 910.

³ E. J. Shellard, P. Tantivatana, and A. H. Beckett, *Planta Medica*, 1967, 15, 366.

⁴ J. Haginiwa, S. I. Sakai, N. Aimi, E. Yamanaka, and N. Shinma, *J. Pharm. Soc., Japan*, 1973, 93, 448.